Skip to content
lifestyle.gopreneurs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Zealand Pharma
Resolutions from Zealand Pharma’s Extraordinary General Meeting 2026
May 26, 2026
Zealand Pharma – Transactions related to share buy-back program (weeks 19-20, 2026)
May 24, 2026
Zealand Pharma – Execution framework for share buy-back program
May 23, 2026
Zealand Pharma Announces Financial Results for the First Three Months of 2026
May 23, 2026
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
May 23, 2026
The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting
May 22, 2026
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026
May 22, 2026
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
May 22, 2026
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
May 22, 2026
Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
May 21, 2026
←
Previous Page
1
2
3
4
Next Page
→